Actuate Therapeutics Inc. (ACTU) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Actuate Therapeutics Inc. (NASDAQ: ACTU) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.34 (+2.06% 1D, market cap $18.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ACTU ranks #609 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACTU carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KYNB (Kyntra Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $18.5M) and AKTX (Akari Therapeutics plc ADS) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M). Among the 5-stock peer group, ACTU leads on earnings multiple (N/A) while ACTU leads on capital efficiency (-35.0% ROIC).
Per ACTU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001652935), Actuate Therapeutics Inc. generated $63.0M in revenue (-10.6% YoY), -$22.2M in net income, and -$19.2M in free cash flow against $14.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 33.3 (NEUTRAL RANGE)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While ACTU currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.87) and Max Pain ($0.36) forces dealer call-delta covering toward $8.29.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Actuate Therapeutics Inc. (ACTU) surged +2.06% to $0.34, trading at 2% of its 52-week range ($0.33 – $7.9). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Quantisnow report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
WBOC TV report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Premarket movers for Nov. 2, 2026: CLRO and EVGO led gainers while KPTI and DRUG led decliners ahead of the US open.
Oral tablet form expected to allow Company to optimize patient plasma exposure levels with convenient daily dosing of drug Sustained plasma levels of elraglusib expected to have multiple effects on immune cell dynamics w
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -10.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ACTU today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ACTU. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Actuate Therapeutics Inc. (ACTU) ranks #609 by composite RQD confidence (35/100, grade D-) and #835 by equity capitalization ($18.4M). Within this direct 5-issuer industry benchmark cohort, ACTU leads on earnings valuation at N/A trailing P/E, while ACTU leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MCRB currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ACTU at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ACTU
ACTIVE
Actuate Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | +2.06% | $18.4M | Benchmark Subject |
| KYNB Kyntra Bio Inc. | E | 32/100 | — | 91.4% | -35.0% | -2.41% | $18.5M | /kynb-vs-actu → |
| AKTX Akari Therapeutics plc ADS | D- | 37/100 | — | — | -35.0% | -4.85% | $18.8M | /aktx-vs-actu → |
| MCRB Seres Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | +3.39% | $17.8M | /mcrb-vs-actu → |
| COCP Cocrystal Pharma Inc. | D- | 36/100 | — | — | -35.0% | +6.53% | $19.2M | /cocp-vs-actu → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Actuate Therapeutics Inc. (ACTU) reported GAAP revenue of $63.0M (-10.6% vs. FY2024 revenue of $70.5M , and -9.9% cumulative change since FY2023) , GAAP net income of -$22.2M, operating cash flow of -$19.2M, and free cash flow of -$19.2M (+12.1% YoY). On the balance sheet, ACTU closed FY2025 with $14.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $63.0M | -$22.2M | -$19.2M | -$19.2M | $14.0M | — |
| FY2024 (FY) | 2024-12-31 | $70.5M | -$27.3M | -$21.8M | -$21.8M | $9.3M | — |
| FY2023 (FY) | 2023-12-31 | $69.9M | -$24.7M | -$21.6M | -$21.6M | — | — |
As of 2026-11-03, Actuate Therapeutics Inc. (NASDAQ: ACTU) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.34 (+2.06% 1D, market cap $18.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ACTU ranks #609 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACTU carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KYNB (Kyntra Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $18.5M) and AKTX (Akari Therapeutics plc ADS) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M). Among the 5-stock peer group, ACTU leads on earnings multiple (N/A) while ACTU leads on capital efficiency (-35.0% ROIC).
Per ACTU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001652935), Actuate Therapeutics Inc. generated $63.0M in revenue (-10.6% YoY), -$22.2M in net income, and -$19.2M in free cash flow against $14.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
ACTU last traded at $0.34 (+2.06% on volume of 295,536 shares), positioning the stock -60.92% below its 50-day simple moving average ($0.87) and -83.89% below its 200-day simple moving average ($2.11). Across its 52-week range of $0.33 to $7.90, ACTU sits at the 0.1% percentile with a 14-day RSI of 33.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.38).
Actuate Therapeutics Inc. (ACTU) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.34 (+2.06% 1D, market capitalization $18.4M).
Actuate Therapeutics Inc. Is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry,. The FY 2025 and FY 2024 revenue figures are reported as —, and the company's model of monetization is not detailed in the sources.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Actuate Therapeutics Inc. (ACTU) reported $63.0M in annual revenue (up from $70.5M in FY2024, -10.6% YoY) and -$22.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($69.9M revenue, -$24.7M net income) through FY2025, ACTU scaled operating cash flow to -$19.2M and free cash flow to -$19.2M, backed by $14.0M in total assets against $0 in total debt.
Upstream and downstream dependencies cannot be identified from the source data. A prospective investor should note that the absence of mapped links means second-order bottlenecks cannot be assessed here, and any ripple analysis would require information outside this source set.
Real-time company headlines, analyst actions, and sector developments for Actuate Therapeutics Inc. (ACTU) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Quantisnow report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
WBOC TV report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Actuate Therapeutics Inc. (ACTU) market action, institutional positioning, and fundamental catalysts.
Picked up a starter position in ACTU in my $100K Virtual Cash book at $0.34. Recent financings priced an $11.0 Million underwritten offering and a $9.96 Million stock-and-warrant raise, which bolster the cash balance of $13.2M.. Trading inside a $0.33–$7.90 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
Both sides have a point here — ACTU's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
The company reports ROIC of -35%, zero revenue, and negative free cash flow of -$19.2M, with the stock down to $0.37 from a 52-week high of $7.9.. Look at the math on ACTU: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $0.30 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: